- Trials with a EudraCT protocol (659)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
659 result(s) found for: Death Receptor.
Displaying page 1 of 33.
EudraCT Number: 2005-001193-28 | Sponsor Protocol Number: AMB-320/321-E | Start Date*: 2005-11-08 |
Sponsor Name:Myogen, Inc | ||
Full Title: ARIES-320/321-E “A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321" | ||
Medical condition: Pulmonary Arterial Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-004557-24 | Sponsor Protocol Number: UKM17_0056 | Start Date*: 2019-07-29 | |||||||||||
Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel | |||||||||||||
Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003991-37 | Sponsor Protocol Number: AGO/2006/009 | Start Date*: 2006-12-13 | |||||||||||
Sponsor Name:University Hospital Gent | |||||||||||||
Full Title: Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome | |||||||||||||
Medical condition: Marfan syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003065-17 | Sponsor Protocol Number: CRAD001Y24135 | Start Date*: 2013-05-16 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally ad... | |||||||||||||
Medical condition: Estrogen receptor positive metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) NL (Completed) PT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001634-17 | Sponsor Protocol Number: 2015.0704 | Start Date*: 2015-12-24 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: 18FDHT-PET to visualize the effect on the androgen receptor level by bicalutamide | ||
Medical condition: androgen receptor positive metastatic breast cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002469-37 | Sponsor Protocol Number: CA209-7FL | Start Date*: 2020-01-29 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With Hi... | |||||||||||||||||||||||
Medical condition: Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) DE (Completed) CZ (Completed) FR (Completed) PL (Completed) NL (Completed) BE (Completed) DK (Completed) FI (Completed) IE (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing) RO (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000693-30 | Sponsor Protocol Number: 56UCS2017 | Start Date*: 2019-11-25 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. | |||||||||||||
Medical condition: Women with confirmed high grade serous or endometrial epithelial ovarian cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002187-22 | Sponsor Protocol Number: 001 | Start Date*: 2005-04-05 |
Sponsor Name:Ullevål University Hospital | ||
Full Title: Scandinavian Candesartan Acute Stroke Trial | ||
Medical condition: Acute stroke (ischemic or haemoragic) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) DK (Completed) BE (Completed) EE (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003179-12 | Sponsor Protocol Number: MN0511_1 | Start Date*: 2012-01-09 |
Sponsor Name:University Hospital of Wuerzburg, Medical Director | ||
Full Title: Mineralocorticoid Receptor antagonists in End stage reNal DiseAse | ||
Medical condition: Hemodialysis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001054-34 | Sponsor Protocol Number: D0816C00018 | Start Date*: 2018-01-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: LUCY - Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-... | |||||||||||||
Medical condition: Metastatic Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) HU (Completed) FR (Ongoing) PL (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002113-39 | Sponsor Protocol Number: BAY88-8223/16298 | Start Date*: 2014-10-29 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ... | |||||||||||||
Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002114-23 | Sponsor Protocol Number: BAY88-8223/17096 | Start Date*: 2015-10-26 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus whe... | |||||||||||||
Medical condition: Metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) DE (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006111-62 | Sponsor Protocol Number: CRAD001JDE49 | Start Date*: 2012-07-11 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination Wi... | |||||||||||||
Medical condition: The trial aims to evaluate the efficacy, safety, quality of life and health resources in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with N... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005715-22 | Sponsor Protocol Number: D6990C00001 | Start Date*: 2006-02-21 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone ma... | ||
Medical condition: postmenopausal women with hormone receptor positive early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Prematurely Ended) NO (Completed) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2017-001548-36 | Sponsor Protocol Number: CO40016 | Start Date*: 2017-12-18 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE III STUDY OF IPATASERTIB IN COMBINATION WITH PACLITAXEL AS A TREATMENT FOR PATIENTS WITH PIK3CA/AKT1/PTEN-ALTERED, LOCALLY ADVANCED OR METASTATI... | ||||||||||||||||||
Medical condition: Locally advanced unresectable or metastatic triple-negative (estrogen receptor, progesterone receptor, and HER2 negative) breast cancer or locally advanced unresectable or metastatic hormone recept... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) PL (Completed) BE (Completed) FR (Completed) GR (Completed) SI (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002942-12 | Sponsor Protocol Number: P04737 | Start Date*: 2007-10-22 | |||||||||||
Sponsor Name:Schering-Plough Research Institute | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Dis... | |||||||||||||
Medical condition: Documented coronary artery disease, postischemic cerebrovascular disease or peripheral artery disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DK (Completed) NL (Completed) SE (Completed) PT (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed) IT (Completed) ES (Completed) AT (Completed) DE (Completed) PL (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004493-26 | Sponsor Protocol Number: D9670C00001 | Start Date*: 2020-09-02 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) versus Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose... | |||||||||||||
Medical condition: HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) DK (Ongoing) NL (Ongoing) HU (Ongoing) PL (Ongoing) DE (Ongoing) BE (Ongoing) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) PT (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004869-27 | Sponsor Protocol Number: MK-3475-756 | Start Date*: 2019-05-03 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Es... | |||||||||||||
Medical condition: High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) HU (Ongoing) BE (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000794-31 | Sponsor Protocol Number: October2011,version5 | Start Date*: 2011-06-15 | |||||||||||
Sponsor Name:Dept. of Pharmacology | |||||||||||||
Full Title: Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004925-64 | Sponsor Protocol Number: Cola | Start Date*: 2008-05-28 |
Sponsor Name:HSK Research GmbH | ||
Full Title: A Phase II Controlled Study of pegylated liposomal Doxorubicin (PLD, CAELYX) and Carboplatin for the Preoperative Treatment of Advanced Breast Cancer | ||
Medical condition: A PLD and Carboplatin based neoadjuvant treatment regimen with less cardiotoxicity (as compared to other anthracyclines) and generally reduced side effects is of interest not only for breast cancer... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.